Ovarian cancer drug approved for NHS use will prolong lives
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
Original Source
Read the full article at Theconversation →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.